FDA authorizes new companion diagnostic for KMTA-rearranged acute leukemia
The US Food and Drug Administration (FDA) has granted a De Novo Classification Request for the CytoCell KMT2A Breakapart FISH Probe Kit PDx,
Leukemia
Acute Lymphoblastic Leukemia
MPN News
SOHO 2025
Dr. Cheema discusses SOHO 2025 abstract on PV, GLP-1a therapy
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Asfand Yar Cheema, MD, resident physician
IMS 2025
Multiple Myeloma
Linvoseltamab shows strong 1st results in high-risk smoldering myeloma
The study was led by Paula Rodríguez-Otero, MD, PhD, a consultant hematologist at Clínica Universidad de Navarra, on September 19, 2025, who presented
IMS 2025
Interim analysis shows promise in belantamab-based maintenance in high-risk MM
In patients with high-risk multiple myeloma, maintenance therapy with belantamab, pomalidomide, and dexamethasone (BPD) demonstrated encouraging activity and a manageable safety profile, according
IMS 2025
Multiple Myeloma
Daratumumab raises early infection risk in myeloma
Daratumumab raises early infection risks in patients treated with multiple myeloma, according to an oral abstract presented on September 17, 2025, at the
Lymphoma News
SOHO 2025
Cellular Therapy
News
Video Interviews
Dr. Karmali discusses phase 2 TRANSCEND FL study results
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Reem Karmali, MD, an associate professor
MPN News
SOHO 2025
GLP-1a therapy tied to better survival, fewer complications in PV
Patients with polycythemia vera (PV) who received GLP-1a therapy had markedly better outcomes than patients who did not, according to a retrospective study
SOHO 2025
Acute Lymphoblastic Leukemia
Early NGS MRD negativity associated with durable remissions in high-risk B-cell ALL
Achievement of early measurable residual disease (MRD) negativity under assessment with next-generation sequencing (NGS) is associated with durable remissions in patients with newly
SOHO 2026
Leukemia News
SOHO 2025
Meetings / Conferences
News
Dr. DiPersio to take the helm as 2025-2026 SOHO president
After the lights go down on SOHO 2025, John DiPersio, MD, PhD, will step into his role as the 2025-2026 SOHO president. Looking
Leukemia News
SOHO 2025
Meetings / Conferences
News
Dr. Mullighan headlines plenary with precision therapy talk Friday afternoon
“I think we’re poised to develop experimental models through genome editing and other approaches,” Dr. Mullighan said. “We’re also using our experience from